| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $1,728,000 | 1 | 100 |
| 3D Investment Partners Pte. Ltd. | Formerly 10% Owner | 0 | $0 | 1 | $1.73M | $-1.73M |
MediciNova, Inc. is a biopharmaceutical firm dedicated to discovering and advancing innovative small molecule therapies for severe illnesses where current treatments are insufficient within the United States. Its robust development pipeline features MN-166 (ibudilast), an oral agent with both anti-inflammatory and neuroprotective properties, currently being investigated for a range of neurological conditions. These include primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral …
Over the last 12 months, insiders at MediciNova, Inc. have bought $0 and sold $1.73M worth of MediciNova, Inc. stock.
On average, over the past 5 years, insiders at MediciNova, Inc. have bought $0 and sold $878,015 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,000 shares for transaction amount of $7,240 was made by Matsuda Kazuko (Chief Medical Officer) on 2020‑03‑13.
| 2026-09-25 | Sale | 3D Investment Partners Pte. Ltd. | Formerly 10% Owner | 640,000 1.3607% | $2.70 | $1.73M | -43.02% | |
| 2022-11-28 | Sale | Nagao Hideki | director | 6,754 0.0116% | $2.25 | $15,197 | -16.17% | |
| 2022-11-22 | Sale | Nagao Hideki | director | 218 0.0004% | $2.13 | $464 | +5.19% | |
| 2022-11-21 | Sale | Nagao Hideki | director | 5,365 0.0112% | $2.18 | $11,696 | +4.69% | |
| 2022-11-17 | Sale | Nagao Hideki | director | 309 0.0006% | $2.18 | $674 | +2.29% | |
| 2021-03-11 | Sale | Nagao Hideki | director | 2,354 0.0052% | $7.40 | $17,420 | -47.29% | |
| 2020-09-15 | Sale | Nagao Hideki | director | 1,000 0.0022% | $5.78 | $5,780 | -11.94% | |
| 2020-03-13 | Matsuda Kazuko | Chief Medical Officer | 2,000 0.0041% | $3.62 | $7,240 | +38.71% | ||
| 2020-03-12 | IWAKI YUICHI | President and CEO | 20,000 0.0451% | $3.10 | $62,000 | +78.59% | ||
| 2017-08-21 | Ishizaka Yoshio | director | 5,000 0.0148% | $5.17 | $25,850 | +71.53% | ||
| 2017-05-15 | Kobayashi Yutaka | director | 2,000 0.0056% | $5.60 | $11,200 | +15.24% | ||
| 2017-05-12 | Kobayashi Yutaka | director | 48,000 0.1421% | $5.62 | $269,760 | +20.44% | ||
| 2016-09-15 | Kobayashi Yutaka | director | 23,600 0.0662% | $6.44 | $151,984 | -10.96% | ||
| 2016-09-09 | Kobayashi Yutaka | director | 20,000 0.06% | $6.67 | $133,400 | -7.75% | ||
| 2016-07-05 | Sale | OBrien Geoffrey | Vice President | 6,600 0.0155% | $6.40 | $42,240 | -22.50% | |
| 2014-12-10 | Kobayashi Yutaka | director | 24,000 0.1054% | $3.54 | $84,960 | +4.48% | ||
| 2014-11-26 | Kobayashi Yutaka | director | 20,000 0.0812% | $3.07 | $61,400 | +11.78% | ||
| 2014-11-20 | Kobayashi Yutaka | director | 26,000 0.1112% | $3.19 | $82,940 | +13.23% | ||
| 2014-11-19 | Ishizaka Yoshio | director | 10,000 0.04% | $2.86 | $28,600 | +18.18% | ||
| 2014-09-11 | Kobayashi Yutaka | director | 20,000 0.084% | $2.95 | $59,000 | +22.68% |
| IWAKI YUICHI | President and CEO | 780683 1.5861% | $1.11M | 15 | 0 | +31.46% |
| Izumi Tatsuo | director | 600000 1.219% | $852,000.00 | 5 | 1 | +8.22% |
| Matsuda Kazuko | Chief Medical Officer | 111746 0.227% | $158,679.32 | 1 | 0 | +38.71% |
| Kalafer Michael E | Chief Medical Officer | 31744 0.0645% | $45,076.48 | 1 | 0 | |
| Kobayashi Yutaka | director | 25000 0.0508% | $35,500.00 | 9 | 0 | +12.44% |
| Ishizaka Yoshio | director | 10000 0.0203% | $14,200.00 | 2 | 0 | +44.86% |
| O'Toole David D | director | 5000 0.0102% | $7,100.00 | 1 | 0 | +8.62% |
| COFFEE MICHAEL DENIS | CBO & Interim CFO | 4000 0.0081% | $5,680.00 | 1 | 0 | <0.0001% |
| Johnson Kirk William | Chief Scientific Officer | 1700 0.0035% | $2,414.00 | 1 | 0 | <0.0001% |
$5,831,763 | 118 | -33.78% | $66.68M | |
$9,405,928 | 107 | 12.61% | $74.85M | |
$17,525,882 | 60 | 5.22% | $64.7M | |
$19,705,388 | 47 | 86.26% | $67.15M | |
$909,129 | 37 | 42.19% | $67.23M |
| Increased Positions | 17 | +58.62% | 387,470 | +7.56% |
| Decreased Positions | 11 | -37.93% | 258,608 | -5.04% |
| New Positions | 9 | New | 305,878 | New |
| Sold Out Positions | 2 | Sold Out | 56 | Sold Out |
| Total Postitions | 35 | +20.69% | 5M | +2.51% |
| Essex Woodlands Management, Inc. | $1,471.00 | 2.26% | 1.11M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $932.00 | 1.43% | 700,385 | +13,808 | +2.01% | 2025-09-30 |
| Blackrock, Inc. | $930.00 | 1.43% | 698,967 | +3,252 | +0.47% | 2025-09-30 |
| Citigroup Inc | $790.00 | 1.21% | 594,057 | +2,100 | +0.35% | 2025-09-30 |
| Geode Capital Management, Llc | $705.00 | 1.08% | 529,702 | +3,810 | +0.72% | 2025-09-30 |
| Ubs Group Ag | $296.00 | 0.45% | 222,267 | +67 | +0.03% | 2025-09-30 |
| Renaissance Technologies Llc | $256.00 | 0.39% | 192,500 | +13,800 | +7.72% | 2025-09-30 |
| State Street Corp | $232.00 | 0.36% | 174,598 | 0 | 0% | 2025-09-30 |
| Northern Trust Corp | $179.00 | 0.28% | 134,743 | -4,995 | -3.58% | 2025-09-30 |
| Susquehanna International Group, Llp | $163.00 | 0.25% | 122,879 | -127,464 | -50.92% | 2025-09-30 |